ReviewCellular and molecular neurobiology2024
Iron Deposition in Parkinson's Disease: A Mini-Review.
Review in Cellular and molecular neurobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Association between iron deposition and emotional disorder in Parkinson's patients: a systematic review and meta-analysis.BMC neurology · 2026Pooled it
- Oxidative stress and inflammation in neurodegenerative disorders.Archives of toxicology · 2026Review
- Environmental hazards and climate change: Unmasking Parkinson's hidden enemies.Journal of Parkinson's disease · 2026Review
- Association Between Substantia Nigra Hyperechogenicity and Central Macular Thickness in Parkinson's Disease.Biomedicines · 2026Article
- Mechanistic insights into anti-parkinson effect of baicalein: from neuroinflammation and cell death to neurogenesis and synaptic plasticity.Molecular biology reports · 2026Review
- Neuroimaging of the monoaminergic system in Parkinson's disease: A narrative review.Neuroimage. Reports · 2026Review
- L-DOPA influences transferrin-dependent iron release at the blood-brain barrier.Fluids and barriers of the CNS · 2026Article
- Iron Dysregulation and Vascular Diseases: A Contemporary Review.Journal of the American Heart Association · 2026Review
- Marine bacterium Stutzerimonas stutzeri mitigates Parkinson's disease pathology in C. elegans via ferroptosis modulation.Scientific reports · 2026Article
- Sex and Diet Biased Effect of L-DOPA on Iron Accumulation in the Ventral Midbrain.Journal of neurochemistry · 2026Article
- Towards a Biologically Defined Diagnosis: Incorporating Pathophysiological Measures Into Parkinson's Disease Clinical Criteria.Parkinson's disease · 2026Review
- Ferroptosis in microglial activation: a systematic review and multidata comparison.Brain communications · 2026Review
- Machine learning-based radiomics modeling of combined subcortical nuclei from quantitative susceptibility mapping for Parkinson's disease diagnosis.Frontiers in aging neuroscience · 2026Article
- Kynurenine pathway in Parkinson's disease: pathophysiological roles and therapeutic interventions.Inflammopharmacology · 2026Review
- Autophagy-lysosomal pathway in neurodegeneration.Molecular neurodegeneration advances · 2026Review
- The role of quantitative susceptibility mapping in dementia with Lewy Bodies.NeuroImage. Clinical · 2026Article
- Sweet orange essential oil and (+)-limonene prevent oxidative stress, reduce inflammation, and apoptosis in differentiated SH-SY5Y neuroblastoma/BV-2 microglia co-culture neurodegeneration models.BMC complementary medicine and therapies · 2025Article
- Longitudinal insights from iron accumulation in motor system of prodromal and clinical Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Beyond Iron: The Roles of CD71 in the Pathophysiology of Cancer-A Comprehensive Review.Journal of clinical medicine · 2025Review
- From Bench to Brain: Translating EV and Nanocarrier Research into Parkinson's Disease Therapies.Biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Iron deposition is crucial pathological changes observed in patients with Parkinson's disease (PD). Recently, scientists have actively explored therapeutic approaches targeting iron deposition in PD. However, several clinical studies have failed to yield consistent results. In this review, we provide an overview of iron deposition in PD, from both basic research and clinical perspectives. PD patients exhibit abnormalities in various iron metabolism-related proteins, leading to disruptions in iron distribution, transport, storage, and circulation, ultimately resulting in iron deposition. Excess iron can induce oxidative stress and iron-related cell death, and exacerbate mitochondrial dysfunction, contributing to the progression of PD pathology. Magnetic resonance imaging studies have indicated that the characteristics of iron deposition in the brains of PD patients vary. Iron deposition correlates with the clinical symptoms of PD, and patients with different disease courses and clinical presentations display distinct patterns of iron deposition. These iron deposition patterns may contribute to PD diagnosis. Iron deposition is a promising target for PD treatment. However, further research is required to elucidate the underlying mechanisms and their impacts on PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.